Biotech & Longevity · Sunday, 11 October 2026
US regulator approves the immune drug Tecentriq for one kind of stage 3 colon cancer, after a trial found it halved the risk of the cancer returning
The FDA approved Genentech's Tecentriq, given with chemotherapy, for colon cancers that cannot fix their own DNA copying mistakes. A trial of 712 patients found it halved the risk of the cancer returning or death. Also: a monthly schizophrenia shot, a new herpes pill, a 140-country survey of trust in science, and the latest on Ebola and the Russian plague-lab death.
50%
lower risk of the cancer returning or death when Tecentriq was added to chemotherapy
the trial's main measure, read as a hazard ratio of 0.50
712
patients in the ATOMIC trial, all with stage 3 colon cancer removed by surgery
711 adults and one child, split at random into two groups
10-15%
of stage 2 or 3 bowel cancers have the broken repair system the approval covers
about 2,000 to 3,000 new cases a year in the UK alone
3
cancer drugs approved by the FDA in seven days
Jaypirca on 2 October, Tukysa on 7 October and Tecentriq on 8 October
The lead story — what happened
-
The FDA, the US agency that decides which medicines can be sold, approved Tecentriq for one kind of colon cancer on Thursday 8 October.
[1] -
Tecentriq is an immune drug made by Genentech, a US drug company. It is added to standard chemotherapy after surgery has removed the tumour.
[1] -
The approval covers stage 3 cancer only, where the cancer had reached nearby lymph nodes, and only after all of it was cut out.
[1] -
It covers only tumours that are 'mismatch repair deficient': their cells have lost the system that fixes copying mistakes in DNA.
[1] -
About 10% to 15% of stage 2 or 3 bowel cancers are this kind, UK researchers say.
[3] -
Immune drugs work unusually well in these tumours, a separate UK trial found.
[3] Their many unfixed DNA mistakes make odd proteins that immune cells can spot. -
The ATOMIC trial split 712 patients at random: half got chemotherapy alone, half got chemotherapy plus Tecentriq.
[1] -
Adding Tecentriq halved the risk of the cancer coming back or the patient dying.
[1] -
Neither group has yet reached the point where half its patients relapsed, so the trial cannot yet say how many years the drug adds.
[1] -
Patients get Tecentriq with chemotherapy for six months, then alone for six more months.
[1] -
It can be given into a vein, or as Tecentriq Hybreza, a shot under the skin, for patients aged 12 or older who weigh at least 40kg.
[1] -
The label warns that it can turn the immune system against healthy organs, and that it can harm an unborn baby.
[1] -
It is the third cancer drug the FDA approved in a week, after Jaypirca on 2 October and Tukysa on 7 October.
[2]
Who is involved
-
Genentech
a US drug company that makes Tecentriq; it is the company named on the approval
-
The FDA
the US government agency that decides which medicines can be sold; it approved Tecentriq on 8 October
-
Patients with stage 3 'mismatch repair deficient' colon cancer
people whose tumour cannot fix its DNA copying mistakes and whose cancer reached nearby lymph nodes; the approval covers only them
How it unfolded
-
2 Oct The FDA approves Jaypirca as a first treatment for a blood cancer
[2] -
7 Oct The FDA approves Tukysa for one kind of breast cancer
[2] -
8 Oct The FDA approves Tecentriq after surgery for one kind of stage 3 colon cancer
[1] -
Next The full prescribing rules are due to be posted on the FDA's drug database
[1]
Where this points
The next thing to watch is whether ATOMIC shows patients on Tecentriq living longer, a figure the FDA notice does not give.
What is pushing on the whole day
The bar and the word are our reading of how hard each one is pushing today. The arrow is where it is heading. The evidence is in the stories below.
Tecentriq's approval covers only colon cancers that cannot fix their DNA mistakes.
A Kenyan man caught Ebola in Congo and travelled by road and air through Uganda before he died in Nairobi.
People with the same depression diagnosis fell into five different brain patterns in a Finnish study.
A drain at the back of the eye was found in mice.
The rest of the day
13 more stories on this beat.
Each with its own sources. None of these is a link to the story above.
-
02
A monthly shot for schizophrenia approved
Teva, an Israeli drugmaker, said on Friday that the FDA had approved Weltruza, a once-a-month injection for adults with schizophrenia.
[4] Schizophrenia is a lasting illness that can bring hallucinations and confused thinking. Weltruza is a slow-release form of olanzapine, an older antipsychotic medicine.[4] [5] It uses a release method from Medincell, a French biotech company, and is their second approved product after Uzedy in 2023.[4] Teva plans to start selling it in the US within weeks.[4] Why it matters — Analysts expect long-acting shots to help people who struggle to keep taking their medicine for an illness that lasts for years.
[5] Medincell's shares rose 16.9% in Paris, and it may earn up to $112 million more from Teva, plus a share of sales.[4] [5] -
03
A new pill for herpes the old drugs miss
The FDA approved Hovilpri, a pill also called pritelivir, for adults with weak immune systems.
[6] It is for herpes sores that did not heal on acyclovir, valacyclovir or famciclovir, the usual drugs.[6] Herpes simplex is a common virus that causes painful blisters on the lips, nose, eyes or genitals, and it stays in the body for life.[6] In a trial of 101 such adults, all sores healed within 28 days in 63% of those on Hovilpri, against 34% on other drugs.[6] Hovilpri63%Other drugs34%Share of patients whose herpes sores had all healed within 28 days, in a trial of 101 adults with weak immune systems. Why it matters — People whose immune systems are weakened, for example by blood cancers, transplants or HIV, get herpes more often and more severely.
[6] Until now their doctors could only switch between drugs the virus resisted, or that patients could not bear.[6] -
04
Trust in science measured in 140 countries
Wellcome, a British charity that funds research, published its Global Monitor survey of more than 140,000 adults in 140 countries.
[7] It found that 52% of Americans trust science 'a lot', against 26% across the world.[7] Worldwide, the share who say science helps most people in their country fell from 42% in 2018 to 37% in 2025.[7] In the US it rose from 48% to 57%.[7] The survey was run as part of the Gallup World Poll.[7] United States52%Whole world26%Share of adults who say they trust science 'a lot', in Wellcome's 2025 survey. Why it matters — STAT, a US health news site, found that the US gap between religious and non-religious people on whether science helps was 24 points, against 5 in other rich countries.
[7] The gap is growing because graduates and non-religious Americans are warming to science faster, not because others are turning against it.[7] -
05
WHO finds no plague case in Russia
The World Health Organization (WHO) said on Saturday that it still does not know what killed a 28-year-old worker at a plague research institute in Irkutsk, Siberia.
[8] She died of pneumonia on 2 October, and about 200 people were quarantined.[8] Russia told the WHO that tests on her and her contacts were negative for the dangerous germs they checked for.[8] The WHO said no plague case has been registered, and it has found no sign that anything is spreading.[8] Why it matters — The WHO called the missing diagnosis the key uncertainty that remains.
[8] Health officials watch closely for deadly pneumonia with no known cause, because the Covid pandemic began with a cluster of exactly that.[8] -
06
Ebola reaches another part of Congo
Ebola has reached Alimbongo, a health area in Congo's North Kivu province, which had four confirmed cases and two deaths by 6 October, the WHO said.
[9] Cases have now been found in 64 health areas across seven provinces.[9] This outbreak is caused by Bundibugyo, a kind of Ebola with no approved vaccine or treatment.[9] By 6 October Congo had 8,728 confirmed cases and 4,205 confirmed deaths, and 2,269 people had recovered.[9] Why it matters — Doctors Without Borders, a medical charity, says a third of confirmed patients are treated in ordinary clinics, partly because the special centres lack beds.
[9] That risks passing the virus to other patients and to staff, while teams are following 80.4% of known contacts against a target of 85%.[9] -
07
New finger-prick tests for river blindness
Researchers in Ghana tested two new quick blood tests for river blindness on 1,700 people in seven communities, in a study published on Sunday.
[11] River blindness is caused by a worm, Onchocerca volvulus, and can take away sight.[11] Some of the communities had been given drugs against it for many years.[11] Both new tests agreed with the existing quick test more than 92% of the time.[11] Against a lab test on skin samples, they caught about 69% to 77% of the 26 infections found.[11] Why it matters — The tests met the WHO's standard for mapping where the worm still lives, but not for deciding when a country can stop handing out the drugs.
[11] The work was funded through USAID, the US government's aid agency.[11] -
08
Five brain patterns inside depression
Researchers at the University of Helsinki in Finland recorded brain activity in 263 people with depression and 75 people without it.
[12] They used MEG, a scanner that picks up the faint magnetic fields made when brain cells fire.[12] The people with depression fell into five groups. In some, brain regions were more tightly linked than normal, and in others less.[12] One group had more trauma symptoms, and another had more problems with drugs or alcohol.[12] Why it matters — Studying a mix of these groups may explain why earlier brain studies of depression disagreed with each other.
[12] The researchers say the scans cannot yet be used to choose a patient's treatment.[12] -
09
Loneliness and years of good health
Researchers at Tulane University in the US followed 277,489 adults aged 40 to 69 who began without any of seven major illnesses, including diabetes, heart disease, cancer and depression.
[13] At age 50, men who were both lonely and isolated could expect about 5.8 fewer years free of mental illness.[13] For women it was about 3.7 years.[13] For physical illness the losses were 2.4 years for women and 1.7 for men.[13] The study shows a link, not proof of cause.[13] Men5.8 yearsWomen3.7 yearsFewer years free of mental illness, from age 50, for people who were both lonely and isolated. Why it matters — A healthier lifestyle reduced the loss linked to having few contacts, but not the loss linked to feeling lonely.
[13] That suggests the two problems need different kinds of help.[13] -
10
Pressing shin bones helped injured brains
Researchers at Southern Medical University in Guangzhou, China, pressed on the shin bones of mice with brain injuries for 2.5 minutes a day for five days.
[14] The treated mice moved and remembered better than untreated mice one week and eight weeks later.[14] Bone cells that sense pressure released three substances into the blood, including BDNF, which helps nerve cells survive.[14] Pigs given a similar treatment lost fewer brain cells.[14] Why it matters — No approved drug restores lost brain function after a brain injury.
[14] All the animals were male, and an outside scientist says the work must be repeated in females, because oestrogen changes how bone responds to pressure.[14] -
11
A drain found at the back of the eye
Researchers at the University of British Columbia and the University of Toronto in Canada found a drainage route at the back of the eye in mice.
[15] They named it the POLO pathway.[15] Tiny vessels under the retina, the light-sensing layer of the eye, carried fluid to nearby lymph nodes within minutes.[15] For more than 100 years scientists had thought the eye had no drains like this.[15] Why it matters — Glaucoma and age-related macular degeneration, two big causes of blindness, involve fluid and waste building up in the eye.
[15] Nobody yet knows whether people have the same route, or whether it can be made to work harder.[15] -
12
A seed-sized nerve stimulator
Engineers at NYU Abu Dhabi and Cleveland Clinic Abu Dhabi built a nerve stimulator the size of a small seed that is put in place through a needle.
[16] It has no battery and no wires.[16] Power comes wirelessly from outside the body, and doctors can adjust its electrical pulses.[16] In early tests, reported in the journal Science Advances, it switched on nerves inside a living body.[16] Why it matters — Treating long-term pain by stimulating a nerve today often means surgery to place a device.
[16] The new device has not yet been shown to ease pain in people.[16] -
13
A common plastic and fatty livers
Researchers at Texas A&M University in the US studied tiny bits of polyethylene, the most widely made plastic, in the laboratory.
[17] It is used in food wrap, containers and the linings of drink cups.[17] Exposure raised signs of fatty liver disease, in which fat builds up inside liver cells. The signs were worse with a fatty, sugary diet.[17] The plastic switched on PPAR-alpha, a protein that controls how the liver handles fat.[17] Why it matters — About a quarter of people worldwide have fatty liver disease.
[17] The researchers say more work is needed to know whether this happens at the amounts people actually take in.[17] -
14
Olive oil before sugar, in mice
Researchers led by Daisuke Yabe of Kyoto University in Japan gave mice olive oil 15 minutes before or after a dose of sugar.
[18] When the oil came first, blood sugar rose less and the stomach emptied more slowly.[18] The oil-first mice also released more of several gut and pancreas hormones, including GLP-1, the hormone that weight-loss drugs like Ozempic copy.[18] The effect held in mice with type 2 diabetes.[18] Why it matters — Blocking either glucagon or GLP-1 alone did not stop the effect, but blocking both weakened it, so several signals work together.
[18] Earlier studies in people found that eating fat or vegetables before carbohydrates helps, and these mouse results suggest why.[18]
How one average can hide two different groups
One number for a whole group mixes people who differ, so it can fit nobody well until the group is split by what really divides it.
The twist
When a group mixes people who differ, its average can sit between them and fit none of them. Splitting the group by what really divides it shows who a result belongs to.
The picture
How it works
- Researchers measure many people and report one number
- The group holds smaller groups that differ a lot
- The one number lands between them and fits none of them
- Split the group by a real difference, such as a gene change
- Each smaller group shows its own, much clearer result
The same force, elsewhere today
Where this chain is also running, in today's other stories.
-
Wellcome's trust survey
The US average for trusting science was high, but splitting Americans by religion showed a 24-point gap, against 5 in other rich countries.
-
Five brain patterns inside depression
One diagnosis, split by brain scans, became five groups with different symptoms, which may explain why earlier studies of the whole group disagreed.
-
Loneliness and years of good health
Split by sex, the years free of mental illness lost to loneliness and isolation were about 5.8 for men and 3.7 for women.
Where you've seen this
School tests
a class average of 60 can come from half the class scoring 90 and half scoring 30
Weather
a day that averages 20C can be a cold night and a hot afternoon
Clothes shops
a shop that stocks only the average size fits very few of its customers
The catch
Split a group enough ways and some split will look different by luck alone, so a result found in a smaller group needs its own test before anyone relies on it.
And the whole of it
Every count in today's paper, from a trial of 712 patients to a survey of 140,000 adults, folds each person into one number. Nobody inside that number can see which smaller group they belong to, and often the people who made it cannot see that either.
What is really going on
Three US drug approvals announced on Thursday and Friday each cover a narrow group of patients: Tecentriq for colon cancers that cannot fix their DNA mistakes, Hovilpri for herpes that resists older drugs, and Weltruza as a monthly shot for schizophrenia.
Why it works on us — A patient's own words, like a tumour that 'melted away', can make a result from 32 people sound like a cure for everyone.
Who gains
-
Genentech
— Tecentriq can now be sold for use after surgery in stage 3 colon cancers that cannot fix their DNA mistakes, a group the trial compared against chemotherapy alone.
[1] -
Medincell
— Its shares rose 16.9% in Paris on the Weltruza approval, and it may earn up to $112 million more from Teva, plus a share of sales.
[5] [4] -
Teva
— It gets a second long-acting schizophrenia shot in the US after Uzedy, and its shares closed 2% higher in Tel Aviv.
[4] -
People with weak immune systems and hard-to-treat herpes
— In the Hovilpri trial, 63% had all sores healed within 28 days, against 34% on other drugs.
[6] -
Health teams in Ghana working to end river blindness
— It now has two field tests good enough to map where the worm still lives.
[11]
Who pays
-
Patients given Tecentriq
— They take it for a year in all, and the label warns it can turn the immune system against healthy organs.
[1] -
Patients and health workers in Congo's ordinary clinics
— Ebola patients are sent there when special centres have no beds, which risks spreading the virus to them.
[9] -
The people quarantined in Irkutsk
— About 200 people were held after the death, and Russia later said its tests on her contacts were negative.
[8] -
Americans without a university degree
— Only 47% of them say science benefits most people, against 71% of graduates. STAT's analysis says science's benefits are not reaching many Americans in ways they can see and feel.
[7]
What nobody knows yet
Open questions from across today’s stories — ours included.
-
01
Whether Tecentriq helps patients live longer, and not only stay free of cancer for longer.
Neither group in the ATOMIC trial has yet reached the point where half its patients relapsed, and the FDA notice gives no survival figure.
[1] -
02
How firm the trial's count of relapses is.
The trial was open-label, so patients and doctors knew who got Tecentriq, and the trial's own doctors judged whether the cancer had come back.
[1] -
03
What patients or health systems will be charged for Tecentriq in this use, and for Weltruza.
The FDA notice gives no figure, and Teva's statement, as reported, names none either.
[1] [4] -
04
What killed the 28-year-old worker at the Irkutsk plague institute.
Russia says tests on her were negative for the germs it checked for, and the WHO calls the missing diagnosis the key uncertainty.
[8] -
05
How far Ebola has really spread in Congo.
Teams were following 80.4% of known contacts against a target of 85%, so some chains of infection are not being watched. A third of confirmed patients are in ordinary clinics, not Ebola centres.
[9] -
06
Whether loneliness causes the lost years of good health, or only goes with them.
The Tulane study followed people over time but did not test a cause. The authors plan trials to find out.
[13] -
07
Whether the five brain patterns of depression call for five different treatments.
The Helsinki researchers say their scans cannot yet be used to choose a treatment.
[12] -
08
Whether the drain at the back of the eye exists in people.
It was found in mice, and the researchers say human studies are needed.
[15] -
09
Whether polyethylene harms livers at the amounts people take in.
The study did not show that its doses match everyday human exposure, and the researchers say more work is needed.
[17] -
10
Whether pressing on bones helps brain injuries in females.
Every mouse and pig in the study was male, and oestrogen changes how bone responds to pressure.
[14]
A new pill, Hovilpri, healed all herpes sores within four weeks in 63% of people with weak immune systems whose sores had not healed on the usual drugs. On other drugs, 34% healed.
Also true today
- Adding the immune drug Tecentriq to chemotherapy after surgery halved the risk of one kind of stage 3 colon cancer coming back, and the US approved it on Thursday.
- In Congo's Ebola outbreak, 2,269 people had recovered by 6 October.
- Everyone tested who had been close to a Russian laboratory worker who died of an unexplained pneumonia was negative, and none of them had fallen ill.
- In the US, the share of adults who say science helps most people rose from 48% in 2018 to 57% in 2025.
More from Biotech & Longevity
Across the beats